EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Drug Targeting MCT4 for Melanoma Treatment to Overcome Resistance to BRAF and MEK Inhibitors

Isabella Spinello, Ernestina Saulle, Giuseppina Bozzuto, Marisa Colone, Luca Pasquini, Lauretta Levati, Simona Caporali, Francesco Facchiano, Catherine Labbaye

International Journal of Molecular Sciences · 19.11.2026 · 27 (22) · 10407

DOI: 10.3390/ijms272210407 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.11.2026. Verfasst von Isabella Spinello und 8 weiteren Autor:innen. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Center for Drug Research and Evaluation, Istituto Superiore di Sanità.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Melanoma patients harboring the BRAFV600E mutation frequently display primary or acquired resistance to BRAF/MEK inhibitors. Understanding this chemoresistant phenotype has highlighted the crucial role of metabolic plasticity, which drives a hybrid phenotype utilizing both glycolysis and oxidative phosphorylation. Metabolic proteins, such as the monocarboxylate transporter MCT4 and its chaperone CD147, are significantly upregulated in untreated melanoma samples compared to normal melanocytes, displaying stage-specific dynamics during disease progression across independent patient cohorts. Therefore, they represent promising therapeutic targets to overcome acquired drug resistance. Our study characterized the clinical profiles of CD147 and MCT4 through bioinformatic analysis of patient datasets and functionally validated their targeting in vitro. Subsequently, the effects of the specific MCT4 and CD147 inhibitors, syrosingopine and AC-73 respectively, and the antioxidant polydatin, were evaluated in the human melanoma cell line A375 and its dabrafenib/trametinib resistant subline A375/DT. Our results indicate that AC-73 and polydatin paradoxically may act as pro-survival factors in parental A375 cells, which are characterized by low oxidative stress and reduced CD147 expression. Conversely, in resistant A375/DT cells, which exhibit high oxidative stress and CD147 overexpression, AC-73 or polydatin could be used to eradicate these cells if combined with cytotoxic agents. Notably, syrosingopine, which can be used in combination with dabrafenib in parental A375 cells, demonstrated the highest efficiency in eradicating the resistant A375/DT cells. Finally, our study identifies MCT4 as a potential therapeutic target in advanced melanoma and its inhibitor syrosingopine as a promising adjuvant drug to circumvent resistance to targeted therapy.

Förderung

  • National Center for Drug Research and Evaluation, Istituto Superiore di Sanità

Zitieren

APA

Spinello, I., Saulle, E., Bozzuto, G., Colone, M., Pasquini, L., Levati, L., Caporali, S., Facchiano, F., & Labbaye, C. (2026). Drug Targeting MCT4 for Melanoma Treatment to Overcome Resistance to BRAF and MEK Inhibitors. International Journal of Molecular Sciences, 27(22), 10407. https://doi.org/10.3390/ijms272210407

Vancouver

Spinello I, Saulle E, Bozzuto G, Colone M, Pasquini L, Levati L, et al. Drug Targeting MCT4 for Melanoma Treatment to Overcome Resistance to BRAF and MEK Inhibitors. International Journal of Molecular Sciences. 2026;27(22):10407. doi:10.3390/ijms272210407

BibTeX
@article{Spinello2026,
  author = {Spinello, Isabella and Saulle, Ernestina and Bozzuto, Giuseppina and Colone, Marisa and Pasquini, Luca and Levati, Lauretta and Caporali, Simona and Facchiano, Francesco and Labbaye, Catherine},
  title = {Drug Targeting MCT4 for Melanoma Treatment to Overcome Resistance to BRAF and MEK Inhibitors},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {22},
  pages = {10407},
  doi = {10.3390/ijms272210407}
}
Kostenlos starten →